Merck Announces Fourth-Quarter 2012 Sales and Earnings Conference Call

Wed Jan 2, 2013 8:00am EST

* Reuters is not responsible for the content in this press release.

WHITEHOUSE STATION, N.J.--(Business Wire)--
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold
its fourth-quarter 2012 sales and earnings conference call with institutional
investors and analysts at 8:00 a.m. EST on Friday, Feb. 1. During the call,
Kenneth C. Frazier, chairman and chief executive officer; Peter N. Kellogg,
executive vice president and chief financial officer; and Adam H. Schechter,
president, Global Human Health, will provide an overview of Merck`s financial
performance for the quarter. 

Investors, journalists and the general public may access a live audio webcast of
the call on Merck`s website at Software
needed to listen to the webcast is available on the corporate website and should
be downloaded prior to the beginning of the webcast. A replay of the webcast
will be available at approximately 11:00 a.m. EST on Feb. 1 and will remain on
the website for 12 months. The quarter's sales and earnings news release and
supplemental financial disclosures also will be available in the Newsroom and
Investor sections of the company's website at 

Members of the media are invited to monitor the call by dialing (706) 758-9928
or (800) 399-7917 and using ID code number 81283478. Journalists who wish to ask
questions are requested to contact a member of Merck's Media Relations team at
the conclusion of the call. 

About Merck

Today's Merck is a global healthcare leader working to help the world be well.
Merck is known as MSD outside the United States and Canada. Through our
prescription medicines, vaccines, biologic therapies, and consumer care and
animal health products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching policies,
programs and partnerships. For more information, visit www.merck.comand connect
with us on Twitter, Facebook and YouTube. 

Forward-Looking Statement

This news release includes "forward-looking statements" within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs and
expectations of Merck`s management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially from those set
forth in the forward-looking statements. 

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest rate
and currency exchange rate fluctuations; the impact of pharmaceutical industry
regulation and health care legislation in the United States and internationally;
global trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new product
development, including obtaining regulatory approval; Merck`s ability to
accurately predict future market conditions; manufacturing difficulties or
delays; financial instability of international economies and sovereign risk;
dependence on the effectiveness of Merck`s patents and other protections for
innovative products; and the exposure to litigation, including patent
litigation, and/or regulatory actions. 

Merck undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. Additional
factors that could cause results to differ materially from those described in
the forward-looking statements can be found in Merck`s 2011 Annual Report on
Form 10-K and the company`s other filings with the Securities and Exchange
Commission (SEC) available at the SEC`s Internet site (

Ron Rogers, 908-423-6449
Carol Ferguson, 908-423-4465 

Copyright Business Wire 2013